Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950045 | 0.86 | IDH1 (0.39) | DYRK1AACHEHDAC1HDAC6IDH1 | |
| SCHEMBL25144874 | 0.84 | DYRK1A (0.36) | DYRK1AACHEHDAC1HDAC6IDH1 | |
| SCHEMBL2956511 | 0.83 | DYRK1A (0.38) | DYRK1ARAF1 | |
| SCHEMBL22056656 | 0.82 | DYRK1A (0.35) | DYRK1AACHEHDAC1HDAC6 | |
| SCHEMBL16854832 | 0.82 | DYRK1A (0.35) | DYRK1AACHEHDAC1HDAC6 | |
| SCHEMBL21676107 | 0.79 | DYRK1A (0.33) | DYRK1AHDAC1HDAC6 | |
| SCHEMBL20757802 | 0.79 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL29324839 | 0.72 | — | — | |
| SCHEMBL14552529 | 0.72 | ACHE (0.36) | ACHE | |
| SCHEMBL21166074 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067629-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-29 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067629-A1 | THERAPEUTIC COMPOUNDS | NPC1, CCR5, FURIN | DYRK1A 4681/4885ACHE 2561/4885HDAC1 85/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | DYRK1A 4862/4885ACHE 3996/4885HDAC1 274/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | DYRK1A 4862/4885ACHE 3996/4885HDAC1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.